Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)
DeviceStudy donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
NCT Number: NCT06895070
The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
UC San Diego Health, La Jolla, California, United States
This is a continuation of the PRESERVE IDE trial to provide additional data evaluating the safety and effectiveness of the XVIVO Heart Assist Transport System. The PRESERVE Continued Access Protocol (CAP) will utilize the XHAT System to preserve donor hearts that may not meet current standard donor heart acceptance criteria with the intention of these hearts being transplanted. The CAP has been implemented to allow patients and physicians access to the XHAT System while a Post-Market Approval (PMA) application is being submitted and reviewed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Recipient:
To be eligible to participate in this study, a recipient must meet all the following criteria:
Exclusion criteria
Recipient:
Donor Inclusion Criteria:
To be eligible to participate in this study, the donor heart must meet the following criteria:
Any one or more of the following:
Donor Exclusion Criteria:
Donor hearts that meet any of the following criteria will be excluded from transplantation in this study:
Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
Time frame: 30 days post transplantation
The percentage of patient treatment success rate at 30-days post transplantation. The treatment success is defined as freedom from treatment failure.
Time frame: Post-operative Day 365.
The percentage of patient survival at 365 days from the date of transplant. The long-term safety success is defined as survival.
Contact information is provided by the study sponsor or research team.
XVIVO Perfusion
Industry
PRESERVE CAP: A Prospective, Multi-Center, Single-Arm, Open-Label Study of Hearts Transplanted After Non-Ischemic Heart Preservation From Extended Donors Continued Access Protocol
Acronym: NIHP-CAP-001
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06426173
Cardiovascular Diseases, Heart Diseases
São Paulo, Brazil
View Trial DetailsNCT07471139
Bleeding, Brain Diseases
View Trial DetailsNCT06478017
Heart Transplant
Los Angeles, California, United States
View Trial DetailsNCT04770012
Cardiac Allograft Vasculopathy, Heart Transplant
Vancouver, British Columbia, Canada
View Trial Details